USPTO 2015–2025 USPTO PatentsView US Corporation

New England Biolabs, Inc.

USPTO PatentsView assignee record - 128 granted patents across 18 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

128

Total patents granted

CPC technology areas

15.5

Avg claims per patent

-17%

5-year filing velocity

The verdict

New holds 128 US patents across 18 technology areas, rank #2,974 of 50,000 tracked assignees.

#2,974
of 50,000 US assignees by volume: Top 17%
by Innovation Score (48.2/100): 15.5
avg claims per patent: -17%
filing velocity, last 5 yrs

Portfolio overview

New England Biolabs, Inc. has been granted 128 US utility patents between 2015 and 2025, placing New England Biolabs, Inc. at rank #2,974 across all assignees tracked by PlainPatent. This portfolio spans 18 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.5 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, New England Biolabs, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, New sits between Luminar Technologies, Inc. (128 patents, rank #2,970) and TK Holdings, Llc (128 patents, rank #2,978) - the closest US assignees by grant volume. The composite Innovation Score of 48.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 58 grants, compared with 70 in the 2015–2019 window, a -17% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. New England Biolabs, Inc.'s 15.5 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 18 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark New England Biolabs, Inc. against peers pursuing similar technology classes.

Luminar

128
Microtech Knives

128
NCR Voyix

128
Netease (Hangzhou…

128
Radio Systems

128
Resonant

128
Shanghai Bilibili…

128
TK Holdings

128
New England Biola… ◀

128

What this shows New holds 128 patents at rank #2,974, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near New

By rank, the assignees closest to #2,974 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in New's primary technology class.

New's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

48 Top 17% higher than 83% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

New England Biolabs, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	26	20.3%
2016	9	7.0%
2017	6	4.7%
2018	16	12.5%
2019	13	10.2%
2020	8	6.3%
2021	12	9.4%
2022	16	12.5%
2023	10	7.8%
2024	9	7.0%
2025	3	2.3%

Which technologies does New England Biolabs, Inc. patent most?

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 101

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 88

C12Y - ENZYMES 62

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 33

C07K - PEPTIDES 24

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 19

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 10

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 9

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 5

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 5

C40B - COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES 3

C12R - INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS 2

C07D - HETEROCYCLIC COMPOUNDS 1

A01N - PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS 1

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 1

Top 15 of 18 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Focused

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#2,974

Across all tracked assignees

Innovation Score

48.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does New England Biolabs, Inc. hold?

New England Biolabs, Inc. holds 128 US granted patents filed between 2015 and 2025, spanning 18 technology areas.

What is New England Biolabs, Inc.'s Innovation Score?

New England Biolabs, Inc. has an Innovation Score of 48.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does New England Biolabs, Inc. focus on?

New England Biolabs, Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 101 patents. The company has filed patents in 18 CPC subclasses total.

Is New England Biolabs, Inc.'s patent filing rate increasing or decreasing?

New England Biolabs, Inc.'s recent filing velocity is -17% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for New England Biolabs, Inc.'s patents?

New England Biolabs, Inc.'s patents average 15.5 claims each. This falls within the standard range, providing solid legal coverage.

How is the New England Biolabs, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

New's 128 grants land it in the top 17% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - New ranks #2,974 of 50,000. Top 50 holders
Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.